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PENILAIAN GENOTOKSISITI KE ATAS EKSTRAK PIAWAI 
AKAR EURYCOMA LONGIFOLIA JACK DAN SINTESIS 
TERBITAN BENZIMIDAZOLE SERTA PENILAIAN  
TERHADAP POTENSI ANTI-KANSERNYA 
 
ABSTRAK 
Dalam kajian ini, potensi genotoksik ekstrak piawai akar, F2 daripada Eurycoma 
longifolia Jack telah dinilai menggunakan cerakin limfoma tikus (MLA) mengikut garis 
panduan OECD. Kerja ini berfungsi sebagai ujian pertama untuk menilai profil 
keselamatan E. longifolia menggunakan sistem in vitro mamalia. MLA berkebolehan 
dalam mengesan spektrum luas kejadian mutasi termasuk mutasi titik dan aberasi 
kromosom. Sel L5178Y/tk
+/-
 telah dirawat dengan 1 hingga 50 μg/mL ekstrak akar 
dalam ketidakhadiran dan kehadiran pengaktifan metabolik S9 bagi tempoh rawatan 3-
jam. Satu cerakin rawatan 24-jam telah dijalankan tanpa pengaktifan metabolik S9.  
 
Hasil kajian menunjukkan tiada peningkatan signifikan dan bergantungan kepekatan 
dalam frekuensi mutan diperhatikan pada kepekatan yang diuji di bawah semua keadaan 
rawatan. Dalam rawatan 24-jam, jumlah pertumbuhan relatif (RTG) yang merupakan 
pengukuran sitotoksisiti telah menurun kepada 33.0% dan 21.6% dalam eksperimen 1 
dan 2 masing-masing pada kepekatan tertinggi, 50 μg/mL. Tindak balas setiap kultur 
ujian telah ditentukan sebagai negatif berdasarkan kriteria piawai yang dicadangkan 
oleh Kumpulan Kerja MLA Bengkel Antarabangsa atas Pengujian Genotoksisiti 
(IWGT). Frekuensi mutan teraruh (IMF) telah didapati kurang daripada faktor penilaian 
global (GEF) dan analisis aliran adalah negatif. Penemuan kajian ini menunjukkan 
xx 
 
bahawa kepekatan sehingga 50 μg/mL ekstrak akar piawai, F2 adalah negatif untuk 
potensi genotoksik dalam kehadiran dan ketidakhadiran pengaktif metabolik. 
 
Satu siri terbitan benzimidazole telah disintesis, dicirikan dan dinilai untuk potensi 
terhadap anti-kanser dalam kajian ini. Semua sebatian telah diuji menggunakan cerakin 
MTS untuk menilai potensi sitotoksik mereka terhadap titisan sel kanser payudara 
MCF7 dan MDA-MB-231. Hasil kajian menunjukkan bahawa sebatian-sebatian 
tersebut tidak mempunyai kesan sitotoksik ke atas kedua-dua titisan sel. Terbitan 
benzimidazole, 2-(4-fluorofenil)-1H-benzimidazole dikaji menggunakan cerakin 
migrasi “transwell” untuk menilai sama ada sebatian tersebut boleh merencat migrasi 
sel MDA-MB-231. Menariknya, sebatian tersebut merencatkan migrasi sel MDA-MB-
231 (p <0.01) dengan ketara pada 100 μM berbanding dengan kawalan. Kajian lanjut 
melibatkan analisis biokimia dan fungsian 2-(4-fluorofenil)-1H-benzimidazole 
berfungsi untuk menilai mekanisme tindakannya. 
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GENOTOXICITY ASSESSMENT OF STANDARDISED ROOT 
EXTRACT OF EURYCOMA LONGIFOLIA JACK AND SYNTHESIS 
OF SOME BENZIMIDAZOLE DERIVATIVES AND EVALUATION 
OF THEIR ANTI-CANCER POTENTIAL 
 
ABSTRACT 
In this study, the genotoxic potential of standardised root extract, F2 of Eurycoma 
longifolia Jack has been assessed using the mouse lymphoma assay (MLA) in 
accordance with OECD guideline. This work serves to be the first test to evaluate the 
safety profile of E. longifolia using the in vitro mammalian system. The MLA is 
capable of detecting a broad spectrum of mutational events include point mutations and 
chromosomal abberations. The L5178Y/tk
+/-
 cells were treated with 1 to 50 µg/mL of 
the root extract in the absence and presence of S9 metabolic activation for 3-h. A 24-h 
treatment assay was performed without the S9 metabolic activation. 
 
The results showed no significant (p > 0.05) and concentration-dependent increase in 
mutant frequency observed at the concentrations tested under all the treatment 
conditions. In the 24-h treatment, the relative total growth (RTG) which is the 
measurement of cytotoxicity was 33.0% and 21.6% in experiment 1 and 2, respectively 
at the highest concentration, 50 µg/mL. The response of each test culture was 
determined as negative based on the standard criteria proposed by the MLA Workgroup 
of the International Workshop on Genotoxicity Testing (IWGT). The induced mutant 
frequency (IMF) was found to be less than the global evaluation factor (GEF) and the 
trend analysis was negative. The findings revealed that concentrations up to 50 µg/mL 
xxii 
 
of standardised root extract, F2 did not exhibit genotoxic potential in the presence and 
absence of the metabolic activator. 
 
A series of benzimidazole derivatives were synthesised, characterised and evaluated for 
their anti-cancer potential in the present study. All the compounds were tested using 
MTS assay to assess their cytotoxicity effects towards the MCF7 and MDA-MB-231 
breast cancer cell lines. The results showed that the compounds did not have cytotoxic 
effect on both cell lines. The benzimidazole derivative, 2-(4-fluorophenyl)-1H-
benzimidazole was studied using the transwell migration assay to evaluate whether the 
compound can inhibit the migration of MDA-MB-231 cells. Interestingly, the 
compound at 100 µM significantly inhibited the migration of MDA-MB-231 cells (p < 
0.01) in comparison with the control. Further investigation involving the biochemical 
and functional analyses of 2-(4-fluorophenyl)-1H-benzimidazole would serve to assess 
its mechanism of action. 
 
 
1 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Genotoxicology  
“Genotoxicity" is a wide term which encompasses mutagenicity, DNA damage, DNA 
adduct formation, sister chromatid exchange and mitotic recombination. The term 
"mutagenicity" restricts to gene mutations as well as structural and numerical 
chromosomal aberrations (Hayashi, 2007). Gene mutations include base pair 
substitutions and frameshift mutations. Base pair substitutions occur through the 
substitution of one or several base pairs in the DNA, and frameshift mutations arise 
from an insertion or deletion of a number of base pairs (Stammberger et al., 2006). 
Structural aberrations are categorised into two types, chromosome or chromatid 
aberrations (clastogenicity). Chromosomal mutations and related events are the cause of 
many human genetic diseases and there is substantial evidence that they are involved in 
cancer development. Numerical aberrations are referred to the changes in the number of 
chromosomes of the normal chromosomal content of a cell (aneugenicity) 
(Stammberger et al., 2006). 
 
1.1.1 DNA damage and repair 
DNA damage can either be ‘endogenous DNA damage’ or ‘environmental DNA 
damage’. Endogenous DNA damage primarily involves hydrolytic and oxidative 
reactions following the interaction between DNA,  reactive oxygen species (ROS) and 
water within the cells whereas the environmental DNA damage refers to external 
2 
 
physical or chemical agents that cause DNA damage (Friedberg et al., 2006). DNA 
damage can occur in the form of strand breaks, either single strand breaks which 
involves only one DNA strand or double-strand breaks in which both double helix 
strands are impaired. The latter is considered more hazardous as it can lead to genome 
rearrangement (Friedberg et al., 2006).  
 
In response to DNA damage as described above, cells have certain mechanisms to 
correct the damage. DNA repair is an active process as daily, millions of cells are 
exposed to various metabolic activities and environmental factors and the majority of 
this exposure leads to structural damage of the DNA. However, the rate and success of 
the repair varies based on the severity of the damage and also other factors which 
include cell types, age of the cells and the extracellular environment. The higher the 
severity of DNA damage, the higher the possibility of ineffective DNA repair, which 
could  lead to either the cells undergoing senescence (irreversible state of dormancy), 
cell death (apoptosis) or permanent alterations of DNA structure and function  leading 
to irregular cell division that could ultimately lead to carcinogenesis (Friedberg et al., 
2006).  
 
As soon as the damage has been detected, specific molecules are brought to the site of 
damage and induce other molecules to bind and form a complex for repair. In the event 
small areas of DNA are affected, such as nearly all oxidative damage as well as single 
strand breaks, the damage will be repaired by DNA base excision repair (BER). BER is 
the most active repair process which allows specific recognition of damaged DNA bases 
3 
 
(Friedberg et al., 2006). The second most important DNA repair mechanism is the 
nuclear excision repair (NER) pathway. NER enzymes recognise damaged lesions by 
their abnormal structure and followed by excision and replacement mechanisms 
(Friedberg et al., 2006). There are two sub-pathways for NER, the global genomic NER 
(GG-NER) and transcription-coupled repair (TCR). Both pathways share the same 
repair mechanisms but with different recognition steps and use different sets of proteins 
(Bohr et al., 1985; Hanawalt, 2002). In principle, GGR works by eliminating the lesions 
from the entire genome whereas TCR repairs the damage at DNA strands that actively 
transcribe the gene (Altieri et al., 2008).  
 
The occurrence of DNA damage during cell cycle phases such as DNA replication 
requires correction to avoid permanent mutation in subsequent DNA replications. A 
repair system called mismatch repair recognises and repairs the incorrect insertion, 
deletion and mis-incorporation during DNA replications and also recombination. For 
instance, the mismatches of G/T or A/C pairing bases are repaired by excising the 
wrong bases and replace it with the right nucleotides (Iyer et al., 2006). 
 
Besides, exogenous DNA damaging agents or endogenous ROS formation can also 
cause DNA double-strand breaks which promote genome rearrangements and thus 
initiate carcinogenesis or apoptosis (Hoeijmakers, 2001; Alteiri et al., 2008). Hence, the 
evolved mammalian system has two mechanisms to repair such damage. The first is by 
homologous recombination (HR) which uses instructions from sister or homologous 
chromosomes for a proper repair of the breaks. The second mechanism is known as 
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non-homologous end joining (NHEJ) where the two severed DNA ends are rejoined in a 
sequence independent manner (Helleday et al., 2007; Weterings and van Gent, 2004). 
 
1.1.2 Carcinogenesis 
In general, genotoxicity describes the deleterious action on the cell genome affecting its 
integrity. Genotoxic chemicals are known to produce mutagenicity (the capacity to 
induce permanent alteration in the genetic material within living cells) and may proceed 
to carcinogenicity (formation of cancer). Mutagenesis is important in the carcinogenesis 
process however not all carcinogenesis is due to mutagens. This is due to the fact that 
carcinogenesis could also occur via epigenetic (not involving the DNA) mechanisms. 
 
Genotoxins or mutagens can both give rise to carcinogenesis. Irregular cell division 
during cell cycle due to mutations and ineffective repair processes may lead to this 
hazardous process. In spite of the significant role of mutations in carcinogenic processes, 
not all types of mutation may lead to tumour or cancer formation. Mutations of proto-
oncogenes will normally modify their normal expression and activity, and they can be 
transformed to oncogenes via mutation. This can lead the cell to proliferate abnormally. 
Tumour suppressor gene (TSG), another important gene that regulates the normal cell 
growth and mitosis also plays a vital role in cancer formation. In cases of cellular stress 
or DNA damage, the TSG will suppress normal function and promote cell cycle arrest, 
to allow adequate time for repair and to prevent mutations from passing to new cells. 
However, in the event the TSG itself has been mutated, the original functions of it can 
be switched off and DNA damage without repair may lead to mutation. One of the most 
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important TSG is p53. The mutation of p53 has been reported to have high prevalence 
in human cancers (50 %) and cells that lack this p53 exhibit genetic instability and 
defects in cell-cycle control (Hollstein et al., 1991; Greenblatt et al., 1994; Soussi and 
Wiman, 2007).  
  
The formation of tumour or cancer involves a series of complex processes which 
generally proceeds over years. The multistage process of carcinogenesis comprises of 
three main stages namely, initiation, promotion and progression (Cohen, 1991; Mehta, 
1995; Hasegawa et al., 1998; Trosko, 2001) as depicted in Figure 1.1. DNA damage is 
the earliest event and has a key role in carcinogenesis. Thus, following DNA damage 
during initiation stage, the cell undergoes mutations which induce proliferation but not 
differentiation (Trosko, 2001). Rapidly dividing cells have less time for DNA to get 
repaired and to remove the DNA-adducts (covalent binding of chemicals with DNA) 
(Richardson et al., 1986; Frowein, 2000) and these cells may remain dormant over time 
(Player et al., 2004) until the next stage, promotion. This second stage starts when the 
influence of promoter increases the cell proliferation in susceptible tissues, which 
eventually enhance the genetic changes and also the cell growth control (Mehta, 1995; 
Oliveira et al., 2007). The ‘promoted’ cells which survived apoptosis may proceed to 
the final stage, ‘progression’ which cells are characterised by irreversibility, genetic 
instability, rapid growth, invasive, metastasize and have various changes biochemically, 
metabolically and morphologically (Pitot and Dragan, 1991; Butterworth  et al., 1998; 
Dixon and Kopras, 2004; Oliveira  et al., 2007). 
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Figure 1.1: Stages of chemical carcinogenesis (Source: Oliveira et al., 2007) 
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1.1.3 Genotoxicity testing 
The field of genetic toxicology began in the 1960s in conjunction with a number of 
seminal conferences held focusing on chemical mutagens, particularly their effects on 
germ cells and the risk to future generations. Although germ-cell risk was the initial 
concern, this was broadened in the 1970s when evidence relating genotoxicity and 
carcinogenicity began to accumulate. This was further supported by the use of in vitro 
metabolic activation systems capable of producing electrophilic metabolites. From then 
onwards, various national expert committees were formed to advise on the type of 
approach that should be taken to screen new chemicals for carcinogenic risk (and any 
potential heritable effects). Consequently, many guidelines have been prepared over the 
past 25 years describing the in vitro and in vivo tests designed to identify compounds 
that induce genetic damage directly or indirectly through various mechanisms 
(Gatehouse, 2007; ICH, 1997). Internationally, two main bodies are responsible for 
providing the guidance and tests methods in assessing genotoxicity which are the 
Organisation for Economic Cooperation and Development (OECD) and International 
Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. The guidance and methods are continuously reviewed 
and refined to improve the approaches for genotoxicity testing and assessment and also 
to provide a common strategy to increase the harmonisation of the genotoxicity testing 
and risk assessment due to the difference in legislation between countries (Muller et al., 
2003).   
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As part of the registration requirement, chemicals (natural or synthetic) used for 
pharmaceutical products or any other consumer products need to be assessed for 
genotoxic potential. ICH developed a standard approach to conduct the testing using 
both in vitro and in vivo methods in predicting the genotoxicity. The following standard 
test battery has been recommended (ICH, 1997):  
1)   A test for gene mutation in bacteria 
2)   An in vitro test with cytogenetic evaluation of chromosomal damage with  
  mammalian cells or an in vitro mouse lymphoma assay  
3)   An in vivo test for chromosomal damage using rodent hematopoietic cells 
 
The bacterial reverse mutation test (Ames test) utilises strains of Salmonella 
typhimurium and Escherichia coli to detect point mutations which involve substitution, 
addition or deletion of one or a few DNA base pairs (Ames et al., 1975; Maron and 
Ames, 1983; Gatehouse et al., 1994). Principally, this test measures the reversion of 
mutations (incapability of synthesizing the essential amino acid required for normal 
growth) carried by the test strains. The revertant bacteria are detected by their ability to 
grow and form colonies in the absence of the amino acid required by the parent test 
strain. This test is commonly used as an initial screen for genotoxic potential (OECD 
Guideline 471, 1997). A comprehensive evaluation of a database for the Ames test of 
over 540 chemicals by Kirkland et al. (2005) confirmed that the sensitivity and 
specificity of the test was around 60 % and 73.9 %, respectively. Even though the Ames 
test utilizing prokaryotic cells is versatile and rapid, the intrinsic differences between 
prokaryotic and eukaryotic cells in terms of genome structure and organisation 
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necessitate the use of mammalian test systems within any screening battery designed to 
detect the broad spectrum of genotoxins (Gatehouse, 2007).  
 
The mouse lymphoma assay (MLA) is one of the tests which employs the mammalian 
cells in evaluating mutagenesis. The first test was established by Clive and his colleague 
in 1970’s (Clive and Spector, 1975; Clive et al., 1979). Ever since the assay was 
gradually optimised until it is widely acceptable for genotoxicity testing. In principle, 
MLA uses the thymidine kinase (tk) gene of the L5178Y/tk
+/-
 -3.7.2C mouse lymphoma 
cell line as a reporter gene of mutation. The tk gene is located on chromosome 11 in 
mouse cells and on chromosome 17 in humans (Clive et al., 1987). The tk mutated, tk
-/-
 
cells are resistant to the lethal pyrimidine analogue, TFT which is toxic to normal cells 
(causing inhibition of cellular metabolism and halts the cell division). In MLA, the test 
agent is assessed with or without exogenous metabolic activation system (post 
supernatant rat liver S9 induced with Aroclor 1254 or phenobarbital/β-naphthoflavone) 
for appropriate time points (3 or 4-h with and without S9 and also 24-h without S9). 
Exogenous metabolic activation system is important as it mimics the in vivo metabolism 
thus converting the compound into its metabolically active form (Prieto-Alamo et al., 
1996). 
 
Alternative in vitro tests which can be used include the chromosome aberration test or 
micronucleus test, employing other mammalian cell lines such as Chinese Hamster 
Ovary cell lines (CHO, V79) or human lymphoblastoid cells (TK6) which detect 
different end-point of genetic events such as at hypoxanthine-guanine phosphoribosyl 
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transferase (HPRT) or a transgene of xanthine-guanine phosphoribosyl transferase 
(XPRT) (USFDA/CFSAN, 2006). 
 
1.2 Safety concern on the use of pharmaceutical from plant 
Plants have been a source of medicines for thousands of years (Samuelsson, 2004). The 
World Health Organisation (WHO) has estimated that 65-80 % of the world’s 
population use traditional medicine as their primary health care. Pharmaceuticals from 
plants represent the majority of this health care and are growing in use especially in 
developing countries (Drew and Myers, 1997). In Malaysia, the safety of herbal 
medicines or pharmaceuticals from plants is regulated under a government agency, 
National Pharmaceutical Control Bureau (NPCB) which is a designated WHO 
Collaborating Centre for Regulatory Control of Pharmaceuticals.  
 
There is a common belief among us that anything ‘natural is safe’. The ‘father’ of 
toxicology, Paracelsus has made an important statement 500 years ago concerning 
safety which was ‘All substances are poisons; there is none that is not a poison. The 
right dose differentiates a poison and a remedy’ (Timbrell, 2001). This statement is 
applicable to all and includes the natural products as well. Since herbal medicines are 
commonly supplied as dietary supplements or without prescription, they should be used 
with caution, as the herbal medicines used in irregular, high doses or in combination 
with other medications, may pose toxic effects. The toxic effects can range from 
allergic reactions to cardiovascular, hepatic, renal, neurological and dermatological 
effects (Pharmar, 2005). Therefore, it is essential to assess the safety of 
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phytotherapeutic compounds because their usage has a major impact on the health of 
mankind (Marques et al., 2003). 
 
1.3 The Plant Eurycoma longifolia Jack 
1.3.1 Description of the plant 
Eurycoma longifolia Jack is a tropical herbal plant belonging to the Simaroubaceae 
family (Figure 1.2). This species is indigenous to South-East Asian countries such as 
Malaysia, Indonesia and Vietnam. This plant is locally known as ‘Tongkat Ali’ and it is 
found to be growing wildly in the jungle slopes of Malaysia. It is also well known as 
‘Pasak Bumi’ in Indonesia and ‘Cay ba binh’ in Vietnam. This plant is an evergreen 
slow growing tree, which can reach a maximum height of 15-18 metres after 
approximately 2-3 years of cultivation. The roots harvested after 4 years of cultivation 
are usually suitable for commercial purposes. The leaves are pinnate, spirally arranged, 
and can grow 10-15 inches long, while the flowers are produced in large panicles. The 
fruits appear green in color, and turn to dark red after ripening (Bhat and Karim, 2010). 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The photo of Eurycoma longifolia Jack 
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1.2.2 Pharmacological properties of the plant 
A variety of bioactive constituents have been isolated and characterised from                
E. longifolia, especially from the root. Some of them include canthin-6-one alkaloids, 
quassinoids, squalene derivatives and biphenylneolignans (Kardono et al., 1991; Morita 
et al., 1993a; Morita et al., 1993b; Itokawa et al., 1993; Ang et al., 2002; Bedir et al., 
2003; Morita et al., 1992). The different parts of the plant are traditionally claimed to 
have anti-malarial, aphrodisiac, anti-microbial and anti-pyretic activities (Bhat and 
Karim, 2010).  
 
For instance, the anti-malarial property of E. longifolia standardised root extracts 
(TA164) has been investigated and it was shown that the combination treatment of the 
extract and artemisinin suppressed Plasmodium yoelii infection in the experimental 
mice (Mohd Ridzuan et al., 2007). In another study, bioactivity-guided fractionation of 
the ethanolic extract of the roots of E. longifolia was studied by Chan et al. (2004) for 
the possible anti-plasmodial activity on the lactate dehydrogenase activity of in vitro 
chloroquine-resistant Gombak A isolate and chloroquine-sensitive D10 strain of 
Plasmodium falciparum parasites. The results revealed that four quassinoids namely, 
eurycomanone, 13,21-dihydroeurycomanone, 13α(21)-epoxyeurycomanone and 
eurycomalactone, and an alkaloid, 9-methoxycanthin-6-one, displayed higher anti-
plasmodial activity against Gombak A isolate but were less active against the D10 strain 
when compared with chloroquine. 
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Besides that, a pharmacologically active fraction, F16 from E. longifolia has been 
reported to inhibit the proliferation of MCF-7 human breast cancer cells through 
apoptotic pathway accompanied by specific proteolytic cleavage of poly (ADP-ribose) 
polymerase-1 (PARP-1). The apoptosis has been shown to occur independently of 
caspase-9 enzyme and p53 protein (Tee et al., 2007). The methanol, n-butanol, and 
chloroform extracts of the roots of E. longifolia have also been shown to have cytotoxic 
effect on KB, DU-145, RD, MCF-7 and CaOV-3 cancer cell lines while no significant 
effect was observed on normal kidney cells, MDBK (Nurhanan et al., 2005). 
 
Ang et al. (2004) assessed sexual arousal in sexually sluggish old male rats, (24 months 
old, retired breeders). The rats were administered with 200, 400, or 800 mg/kg of          
E. longifolia extract (2 times daily, for 10 days) with control rats receiving 3 mL/kg of 
normal saline. They studied the aphrodisiac effects by visualizing the act of yawning 
and stretching (alone or with stretching) which has been considered as identity for 
sexual arousal. The results indicated that rats administered with the extract at various 
doses increased yawning and stretching, which was highest at the dose of 800 mg/kg. 
The findings demonstrated the effect of the E. longifolia extract on the aphrodisiac 
activity. 
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1.4 Cancer 
Cancer is a genetic disease resulting from mutations that occur due to the abnormalities 
in DNA sequence (Futreal et al., 2001). The hallmarks of cancer comprise six biological 
capabilities include sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis. As normal cells develop progressively to a 
neoplastic state, they acquire a sequence of these hallmark capabilities that enable them 
to become tumourigenic and ultimately malignant (Hanahan and Weinberg, 2011). The 
International Agency for Research on Cancer (IARC) has estimated about 12.7 million 
cancer cases and 7.6 million cancer deaths worldwide in 2008 (Ferlay et al., 2010). The 
increasing burden of cancer constantly demands the discovery of new anti-cancer agents 
with enhanced therapeutic effect. 
 
1.4.1 Breast cancer 
Breast cancer continues to be the most prevalent cancer and the leading cause of cancer 
death in females worldwide, comprising 23 % (1.38 million) of the total new cancer 
cases and 14 % (458,400) of the total cancer deaths in 2008 (Ferlay et al., 2010). In 
Malaysia, a total of 18, 219 new cancer cases were diagnosed in 2007 and registered at 
the National Cancer Registry published in 2011 (Omar and Tamin, 2011). The most 
frequent cancer in Malaysia is breast cancer accounting for 18.1 % of all registered 
cancer cases. The applications of existing knowledge and emerging findings in the area 
of cancer treatment are essential in preventing a substantial proportion of the worldwide 
burden of breast cancer. 
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1.4.2 Estrogen receptor and breast cancer  
Estrogen signaling and the estrogen receptor (ER) are associated with breast cancer 
progression, and the majority of the human breast cancers start out as estrogen 
dependent and express the estrogen receptor. The binding of estrogen to any of the 
structurally and functionally distinct ERs (ERα and ERβ) mediates its biological effects 
(Thomas and Gustafsson, 2011). ERα is the major ER subtype in the mammary 
epithelium which plays an important role in mammary gland biology (Warner et al., 
1999; Curtis Hewitt et al., 2000). The binding of estrogen to ERα translocates the 
ligand-activated ERα to the nucleus, and eventually stimulates gene transcription 
(McKenna et al., 1999; McDonnell and Norris, 2002). ER signaling is complex, 
involving coregulatory proteins and also genomic and extranuclear actions (Barnes et al., 
2004). 
 
There are also breast cancers that do not possess ERs and they are known as ER-
negative breast cancers. ER-negative tumors are morphologically and phenotypically 
distinct from ER-positive breast cancer (Putti et al., 2004). Another subtype of breast 
cancer is the triple-negative breast cancer, characterised by tumors that do not express 
estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes. This subtype put 
forward an important clinical challenge because they do not respond to endocrine 
therapy or other available targeted agents (Hudis and Gianni, 2011). 
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1.4.3 Cytotoxicity versus cytostasis 
DNA damage and the subsequent induction of apoptosis is a primary cytotoxic 
mechanism of many anti-cancer agents, including alkylating agents, platinum 
compounds, topoisomerase inhibitors, and the anti-metabolites (Cepeda et al., 2007; 
Montecucco and Biamonti, 2007). Cytostasis is where the cancer cells are not killed but 
instead they are stopped from proliferating. A true cytostatic agent should halt the 
growth of tumours and could prevent the development of metastases without affecting 
tumour shrinkage (Houghton and Houghton, 1996; Gelmon et al., 2004). It could be 
argued that all microtubule-targeting agents from vincristine to paclitaxel and, more 
recently, the epothilones are inherently cytostatic (Johnson et al., 1963; Altaha et al., 
2002). None of these agents are intrinsically able to cause cytotoxicity. These agents 
arrest cells in mitosis and induce cytostasis by interfering with microtubule dynamics. 
Mitotic arrest is a condition that is poorly tolerated by any cell and must either be 
escaped or resolved by cellular death, hence the cytotoxic activity of these primarily 
cytostatic agents. Although these agents are viewed as cytotoxic, they are in fact 
cytostatic, and the arrest triggers cell death (Blagosklonny and Fojo, 1999). 
 
1.4.4 Cancer cell migration 
Cell migration, including the migration of tumour cells during several steps in the 
metastatic process (Figure 1.3), is a response to environmental cues and results in the 
orderly rearrangement of adhesive structures that connect the cell to the extracellular 
matrix (ECM). There are several adhesion receptor families, including selectins, 
syndecans, the immunoglobulin cell adhesion molecules, cadherins, and integrins. The 
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best-studied adhesion receptors, and of particular interest in migration, are the integrins. 
These are heterodimeric transmembrane protein structures that bind specific 
extracellular sites on the ECM and specific intracellular cytoskeleton adapter proteins 
(Giancotti and Ruoslahti, 1999). As integrins form connections with the extracellular 
environment, they provide structural support. They also mediate intracellular signaling 
through the activation of focal adhesion kinase (Guo and Giancotti, 2004). The native 
ECM of a normal cell is a requisite for survival. Indeed, removal of a cell from its 
supportive matrix can cause that cell to die, also called “anoikis” (Frisch and Ruoslahti, 
1997). In order for a tumour cell to metastasise, it must pass through surrounding 
stromal elements as it migrates toward a lymph or blood vessel. One important class of 
molecules within the invasion front is the matrix metalloproteinase (MMP). MMPs can 
be secreted by neighbouring cells and can become localised and activated on the surface 
of migrating tumour or endothelial cells (Basbaum and Werb, 1996). Once ECM 
barriers at the invasion front have been cleared through proteolytic degradation of 
MMPs, the metastatic cancer cell generates the invasive machinery (Liotta, 1986). 
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1.4.5 Limitations of present anti-cancer drugs 
The four major modes of cancer treatment include surgery, radiation, chemotherapy and 
immunotherapy (Gatenby, 2009). Chemotherapy represents one of the major means for 
cancer treatment, which aims to kill tumour cells or to inhibit their proliferation. 
Chemotherapeutic agents generally have a narrow margin of safety, and are used in 
combination usually given at a maximum tolerated dose to achieve maximum cancer 
cell killing (Chabner and Roberts, 2005). They kill tumour cells by direct cytotoxicity, 
or activating host immune response, inhibiting the proliferation processes of tumor cells, 
and inducing apoptosis (Cotter, 2009). For most anti-cancer drugs, there is a large inter-
individual variability in their pharmacokinetics and this can result in unpredictable 
toxicity and variable anti-tumour effects (Undevia et al., 2005). Drug resistance and 
dose-limiting toxicities are the major problems for the success of cancer chemotherapy 
(Yague and Raguz, 2005). 
Figure 1.3: The metastatic sequence (Source: Geho et al., 2005) 
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Heidelberger et al. (1957) synthesised 5-fluorouracil (5-FU), as an anti-metabolite. 5-
FU and its derivatives are potent mechanism based inhibitors of thymidylate synthase 
(TS), an enzyme which converts 20-deoxyuridine-50-monophosphate (dUMP) to 20-
deoxythymidine-50-monophosphate (dTMP) (Peters et al., 1995). An understanding of 
5-FU mechanism of action has resulted in major therapeutic advances in the past 15 
years. Thus, inhibition of TS by anti-metabolites remains a classic approach and a key 
strategy for suppressing cell division in cancerous tissue (Lehman, 2002). 5-FU has 
been used extensively in the treatment of skin cancers and a variety of solid tumours, 
such as breast, colorectal and gastric cancers. However, the treatment has been found to 
cause neurotoxic and cardiotoxic side effects due to the lack of selectivity of the drug 
towards tumours (Mader et al., 1998). 
 
Anti-estrogens are well established in the treatment of hormone-dependent breast cancer 
(Santen and Harvey, 1999). Tamoxifen (Nolvadex), a non-steroidal triphenylethylene 
derivative is long known to exhibit anti-estrogenic properties in vivo (Studemann et al., 
1997). Although tamoxifen has been very successful in the treatment of breast cancer, it 
is associated with an increased risk of endometrial hyperplasia. In addition, the use of 
tamoxifen is limited by the development of drug resistance (Osborne et al., 1995). 
Therefore, the discovery of new, safe and effective anti-cancer agents is still very much 
in demand. 
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1.5 Benzimidazole 
The benzimidazole nucleus is encountered as a constituent of a variety of bioactive 
compounds that exhibit diverse pharmacological properties. Thus, benzimidazole is 
continuously being an important pharmacophore in drug discovery. The general 
structure of benzimidazole consists of a benzene ring fused to an imidazole ring (Figure 
1.4). 
 
 
 
       Figure 1.4: Benzimidazole 
 
1.5.1 Pharmacological properties 
Albendazole (1) and mebendazole (2), the 2-carbamate benzimidazole derivatives 
possess anti-helmintic activity and they were being employed in clinical use for 70 
decades (Grover et al., 2001; Kohler, 2001). These drugs act by binding to helmintic 
tubulin and eventually disrupting the microtubule structure and functions (Lacey, 1988). 
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In another study, the antioxidant evaluation of some novel benzimidazole derivatives 
showed that compounds 3 and 4 exhibited very good antioxidant capacity with IC50 
values of 1.3 × 10
-5 
M and 1.2 × 10
-5 
M respectively, through the interaction with the 
2,2-diphenyl-1-picrylhydrazyl (DPPH). It was 17-18 fold more potent than the standard 
substance, butylhydroxytoluene (BHT) which showed IC50 value of 2.3 × 10
-4 
M 
(Ayhan-Kilcigil et al., 2005).  
 
 
 
 
(3) 
 
 
 
 
 
 
 
 
(4) 
 
1.5.2 Benzimidazole derivatives and cancer 
In a previous study, the cytostatic activity of compounds 5 and 6 against a panel of 
cancer cell lines was evaluated. The results were expressed as GI50, the molar 
concentration of the compounds needed to inhibit the growth of the cell lines by 50 % 
and LC50, the molar concentration required to kill 50 % of the cells (Boyd and Paull, 
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1995). The highest activity was demonstrated in panels of non-small cell lung cancer, 
melanoma and leukemia, with GI50 in the range of 1.15-7.33 µM and 0.167-7.59 µM, 
respectively, and suitable LC50 with values greater than 100 µM (Abonia et al., 2011). 
 
 
 
 
 
 
 
 
 
(5) 
 
 
 
 
 
 
 
 
 
(6) 
 
In another study, the precursor of trisubstituted benzimidazole, compound 7 has been 
shown to inhibit the proliferation of MDA-MB-231 human breast cancer cells with a 
maximum inhibition of 60 % (Thimmegowda et al., 2008). 
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The compound 8 has been reported to act as potent anti-tumour agent against both the 
murine B16 melanoma (IC50 = 8.5 µM) and human HT-29 colon carcinoma (IC50 = 9.5 
µM) cell lines by inducing apoptosis (Hao et al., 2002). 
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